Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Nushmia Z Khokhar"'
Autor:
Meletios A. Dimopoulos, Jesus San-Miguel, Andrew Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Heather J. Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis, Ajai Chari, Lisa O’Rourke, Kaida Wu, Jordan M. Schecter, Tineke Casneuf, Christopher Chiu, David Soong, A. Kate Sasser, Nushmia Z. Khokhar, Hervé Avet-Loiseau, Saad Z. Usmani
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include
Externí odkaz:
https://doaj.org/article/34bc86c721f547c0b175882c23aa9838
Autor:
Claire Roddie, Lazaros J. Lekakis, Maria A. V. Marzolini, Aravind Ramakrishnan, Yiyun Zhang, Yanqing Hu, Vijay G R Peddareddigari, Nushmia Z Khokhar, Robert W Chen, Silvia Basilico, Meera Raymond, Frederick Arce Vargas, Kevin Duffy, Wolfram Brugger, Maeve O'Reilly, Leigh Wood, David Linch, Karl S Peggs, Carlos Bachier, Elizabeth Lihua Budde, Connie Lee Batlevi, Nancy L. Bartlett, David Irvine, Eleni Tholouli, Wendy Osborne, Kirit M Ardeshna, Martin Pule
Publikováno v:
Blood.
Relapse following CD19-directed chimeric antigen receptor T-cells (CAR-T) for relapsed/refractory large B-cell lymphoma (r/r LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multi-antigen targeting and PD-1 blockade are rational approa
Autor:
Nushmia Z. Khokhar, Denise Bonney, Paul Virgo, Saket Srivastava, Simon Thomas, Ram Jha, Jan Chu, Shaun Cordoba, Robert Chiesa, Persis Amrolia, Yiyun Zhang, Jeremy Hancock, Rachael Hough, Carlotta Peticone, Shimobi Onuoha, Kanchan Rao, Vania Baldan, Kevin Duffy, Paul Veys, Lucy Wheeler, Robert Wynn, William Day, Daniela Soriano Pignataro, Sara Ghorashian, Giovanna Lucchini, Koval Smith, Martin Pule, Liz Clark, Vijay G R Peddareddigari, Mathieu Ferrari, Sabine Domning, Ajay Vora, Frederick Arce Vargas, Muhammad Al-Hajj, Mei Mei Fung, Farzin Farzaneh
Publikováno v:
Nature Medicine
Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation or loss. Dual antigen targeting could potenti
Autor:
Mary E. Guckert, A. Kate Sasser, Pamela L. Clemens, Antonio Palumbo, Steen Lisby, Tahamtan Ahmadi, Paul G. Richardson, Linda Basse, Henk M. Lokhorst, Jakub Krejcik, Charlotte Lemech, Jacob P. Laubach, Howard Yeh, Jianping Wang, Torben Plesner, Ulrik Lassen, Monique C. Minnema, Carla de Boer, Hendrik-Tobias Arkenau, Peter Gimsing, Nushmia Z. Khokhar
Publikováno v:
Blood, 128(14), 1821-1828. American Society of Hematology
Blood, 128(14), 1821. American Society of Hematology
Plesner, T, Arkenau, H-T, Gimsing, P, Krejcik, J, Lemech, C, Minnema, M C, Lassen, U, Laubach, J P, Palumbo, A, Lisby, S, Basse, L, Wang, J, Sasser, A K, Guckert, M E, de Boer, C, Khokhar, N Z, Yeh, H, Clemens, P L, Ahmadi, T, Lokhorst, H M & Richardson, P G 2016, ' Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma ', Blood, vol. 128, no. 14, pp. 1821-1828 . https://doi.org/10.1182/blood-2016-07-726729
Blood, 128(14), 1821. American Society of Hematology
Plesner, T, Arkenau, H-T, Gimsing, P, Krejcik, J, Lemech, C, Minnema, M C, Lassen, U, Laubach, J P, Palumbo, A, Lisby, S, Basse, L, Wang, J, Sasser, A K, Guckert, M E, de Boer, C, Khokhar, N Z, Yeh, H, Clemens, P L, Ahmadi, T, Lokhorst, H M & Richardson, P G 2016, ' Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma ', Blood, vol. 128, no. 14, pp. 1821-1828 . https://doi.org/10.1182/blood-2016-07-726729
Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, has activity as monotherapy in multiple myeloma (MM). This phase 1/2 study investigated daratumumab plus lenalidomide/dexamethasone in refractory and relapsed/refractory
Autor:
Nushmia Z. Khokhar, Hareth Nahi, Neil Rabin, Donna E. Reece, Nizar J. Bahlis, Meletios A. Dimopoulos, Philippe Moreau, Jesús F. San-Miguel, Hartmut Goldschmidt, Albert Oriol, Dina Ben Yehuda, Saad Z. Usmani, Lisa O'Rourke, Christopher Chiu, Sung-Soo Yoon, Mieczysław Komarnicki, Xiang Qin, Paul G. Richardson, Tahamtan Ahmadi, Mary E. Guckert, Kenshi Suzuki, Steen Lisby, Torben Plesner, Robert Z. Orlowski
Publikováno v:
Dimopoulos, M A, Oriol, A, Nahi, H, San-Miguel, J, Bahlis, N J, Usmani, S Z, Rabin, N, Orlowski, R Z, Komarnicki, M, Suzuki, K, Plesner, T, Yoon, S-S, Ben Yehuda, D, Richardson, P G, Goldschmidt, H, Reece, D, Lisby, S, Khokhar, N Z, O'Rourke, L, Chiu, C, Qin, X, Guckert, M, Ahmadi, T, Moreau, P & POLLUX Investigators 2016, ' Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma ', The New England Journal of Medicine, vol. 375, no. 14, pp. 1319-1331 . https://doi.org/10.1056/NEJMoa1607751
Background Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. Methods In this phase 3 trial, we randomly assigned 569 patients with
Autor:
C. Bachier, Eleni Tholouli, Y. Zhang, Martin Pule, David Irvine, Robert T. Chen, N. Bartlet, K. Ardesha, Wendy Osborne, Muhammad Al-Hajj, Maria A V Marzolini, Nushmia Z. Khokhar, Vijay G R Peddareddigari, Simon Thomas, Aravind Ramakrishnan, Maud Jonnaert, P. McSweeney
Publikováno v:
Annals of Oncology. 31:S651
Autor:
Martin Pule, Carlos R. Bachier, Wendy Osborne, Vijay G R Peddareddigari, David Irvine, Kirit M. Ardeshna, Nushmia Z. Khokhar, Maud Jonnaert, Simon Thomas, Aravind Ramakrishnan, Michael Zhang, Maria A V Marzolini, Eleni Tholouli, Peter A. McSweeney, Robert W. Chen, Muhammad Al-Hajj
Publikováno v:
Journal of Clinical Oncology. 38:8001-8001
8001 Background: CD19 directed CAR T cells are effective in patients with r/r DLBCL, however relapses due to CD19 loss or PDL1 upregulation are common. In this study, we evaluate the safety and efficacy of AUTO3, a CAR T targeting CD19/22 with limite
Autor:
Vijay G R Peddareddigari, Simon Thomas, Jim Faulkner, Sonja Zweegman, Tobias Menne, Ekaterini Kotsopoulou, Lydia Lee, Shaun Cordoba, Martin Pule, Virginie Cerec, Kwee Yong, Nushmia Z. Khokhar, Jim Cavet, Muhammad Al-Hajj, Rakesh Popat
Publikováno v:
Blood. 134:3112-3112
Introduction: Chimeric antigen receptor (CAR) T cell therapies directed against B cell maturation antigen (BCMA) have shown significant activity in patients with RRMM, however single antigen targeting with CAR-T cells can result in antigen negative r
Autor:
Vijay G R Peddareddigari, Martin Pule, Muhammad Al-Hajj, Robert T. Chen, Nushmia Z. Khokhar, Maria A V Marzolini, Simon Thomas, Kirit M. Ardeshna, Wendy Osborne, Jane Norman, Maud Jonnaert, Jim Faulkner, Ekaterini Kotsopoulou
Publikováno v:
Blood. 134:246-246
Introduction: CD 19 CAR T cell therapies have shown significant activity in patients with r/r DLBCL, however relapses due to CD19 loss or PDL1 upregulation are common. In this study, we are evaluating the safety and efficacy of AUTO3, a CAR T cell th
Autor:
Vijay G R Peddareddigari, Liz Clark, Shaun Cordoba, Paul Veys, Kanchan Rao, Robert Wynn, Ajay Vora, Martin Pule, Muhammad Al-Hajj, Persis Amrolia, Rachael Hough, Ekaterini Kotsopoulou, Robert Chiesa, Denise Bonney, Nushmia Z. Khokhar, Shimobi Onuoha
Publikováno v:
Blood. 134:2620-2620
Introduction CAR T-cell therapies directed against CD19 or CD22 have shown remarkable activity in r/r B-ALL but relapse due to target antigen down-regulation/loss has been the major cause of treatment failure. To address this, we developed AUTO3, a C